Physician profile
Yi Jiang
NPI 1114210176
$7,279.91
in general payments reported to CMS, 2019-2025
15 companies · $6,304 in 2025
The $6,304 reported for 2025 was more than what 88% of Retina Specialist providers received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $36.64 · 2021: $120 · 2022: $168 · 2023: $250 · 2024: $402 · 2025: $6,304.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $5,068 · Food and Beverage: $1,481 · Travel and Lodging: $393 · Entertainment: $13.76.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $5,068.00 |
| Food and Beverage | $1,481.29 |
| Travel and Lodging | $392.81 |
| Entertainment | $13.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Pharmaceuticals, INC. | $5,836.22 | 2025 | Eylea Hd, Eylea |
| Abbvie INC. | $246.24 | 2024-2025 | |
| Ocular Therapeutix, INC. | $235.51 | 2021-2025 | Dextenza |
| Alcon Vision LLC | $234.40 | 2022-2025 | Clareon |
| Astellas Pharma US INC | $217.75 | 2023-2025 | Izervay |
| Bausch & Lomb Americas INC. | $100.46 | 2023 | Amvisc, Envista Mx60 Iol |
| Coopervision INC. | $98.45 | 2024 | Myday Contact Lens |
| Genentech USA, INC. | $82.98 | 2022-2023 | Vabysmo |
| Regeneron Healthcare Solutions, INC. | $82.37 | 2021-2023 | Eylea |
| Boston Scientific Corporation | $57.33 | 2023 | |
| Carl Zeiss Meditec USA, INC. | $20.07 | 2024 | Lumera 700 |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Sun Pharmaceutical Industries INC. | $17.73 | 2021 | |
| Carl Zeiss Meditec, INC. | $17.24 | 2020 | |
| Optos, INC. | $13.76 | 2024 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yi Jiang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.